
|Videos|May 13, 2016
Use of Somatostatin Analogs in Patients With Neuroendocrine Tumors
Author(s)Wouter W. de Herder, MD, PhD
Wouter W. de Herder, MD, PhD, professor of Endocrine Oncology, Erasmus MC, discusses the use of somatostatin analogs in patients with neuroendocrine tumors, as well as significant clinical trials investigating these agents.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Iberdomide, the First CELMoD for Relapsed/Refractory Multiple Myeloma
2
AMH Testing Predicts Chemotherapy Benefit in RxPONDER Breast Cancer
3
How the Immune System Drives Nerve Growth in TNBC
4
FAQ: When and How to Discontinue Lenalidomide Maintenance in Multiple Myeloma
5



































